380 - Impact of Body Mass Index (BMI) on Disease Free Survival and Likelihood of Pathologic Complete Response in Patients with Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy

Abstract

ABSTRACT Background The BMI is a clinical parameter that although not perfect is often used to measure adiposity. In breast cancer there are multiple studies indicating that overweight/obesity (O/O) is related with lower survival and increased risk of relapse. It has been also reported less likely to achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in O/O patients. Methods We retrospectively reviewed the records of 108 patients diagnosed with invasive locally advanced breast cancer (ILABC) who had been treated with NAC (anthracycline + taxane ± trastuzumab). The aim of our study was to review the impact of BMI on the pCR and the possibility of recurrence. pCR was defined as the criterion of strict pCR breast+nodes. Results From 2004 to 2011, 108 patients received NAC. Based on their weight and height at baseline we divided into two groups; group 1: underweight/normal (BMI Conclusions Despite the retrospective nature of this study we can conclude that the patients with ILABC and O/O have a high risk for relapse and decreased response to NAC. It requires well-designed prospective studies to control confounding factors (dose intensity, chemotherapy regimens, changes in BMI) to get clear answers of these associations. Disclosure All authors have declared no conflicts of interest.